Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deslorelin is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH), classified as a GnRH superagonist or LHRH agonist. It acts by binding to and activating pituitary GnRH receptors, initially causing a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. With continuous administration, it desensitizes these receptors, leading to suppression of sex hormones such as testosterone and estradiol. This results in reversible inhibition of reproductive function. Deslorelin is primarily used in veterinary medicine for chemical castration, management of adrenocortical disease in ferrets, benign prostatic hyperplasia in dogs, induction of ovulation in horses, suppression of reproductive behaviors in birds and small mammals, and temporary contraception[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deslorelin.